Big pharmaceutical companies have been accused of “free-riding on nature(白吃自然)”, after a landmark(里程碑式的) biodiversity fund that invites businesses to put some of their profits back into conservation was left virtually(几乎、实际上) empty.
一项具有里程碑意义的生物多样性基金邀请企业将部分利润回馈自然保护，如今却几乎空空如也，大型制药企业因此被指责“白吃自然”。
The Cali Fund set out to(着手、旨在) raise $1bn (£750m) annually, by asking companies that profit from nature’s genetics(遗传信息、遗传学) to contribute towards conservation in low-income countries. But more than 18 months after the fund was launched(启动、推出), it remains far below this target.
卡利基金的目标是每年募集10亿美元（7.5亿英镑），方式是要求那些从自然界遗传信息中获利的企业，为低收入国家的自然保护出资。然而基金启动已超过18个月，募资额仍远低于目标。
As of(截至) Monday, at the start of the Cop17 biodiversity summit in Armenia, the fund had received just $10,656 in commitments(承诺捐款), of which $7,085 had been deposited(存入、到账).
截至周一，也就是亚美尼亚Cop17生物多样性峰会开幕之际，该基金仅收到10656美元的承诺捐款，其中实际到账的只有7085美元。